Insulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy
|
|
- Nigel Pierce
- 8 years ago
- Views:
Transcription
1 Insulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy Eric RENARD, MD, PhD Endocrinology Dept, Lapeyronie Hospital Montpellier, France e-renard@chu-montpellier.fr
2 Type 2 Diabetes Burnout : What is the Remedy and for Whom? Needles? Or Pump?
3 What is the Current Experience of Glucose Control with Insulin Injections in Type 2 Diabetes?
4 HbA1c (%) 9,5 9 8,5 8 7,5 7 6,5 6 Insulin Therapy in Type 2 Diabetes and Outcomes on HbA1c Abraira et al, VA CSDM, Diabetes Care, 1995, 18: Follow-up of intensively treated group (75 patients) 9,3 OHA+/- INS 7,9 Bedtime INS 7,4 7,4 Bedtime INS+SU p < ,9 INS x 2/d INS x 3-4/d BASAL-BOLUS BOLUS is finally requested to reach target
5 Insulin 100 (IU/day) 80 Insulin Therapy in Type 2 Diabetes and Outcomes on Insulin Daily Doses Abraira et al, VA CSDM, Diabetes Care, 1995, 18: Follow-up of intensively treated group (75 patients, mean BMI = 30.7) OHA +/- INS p < Bedtime INS Bedtime INS+SU 116 INS x 2/d 133 INS x 3-4/d HIGH INSULIN DOSES are often needed to reach target
6 Fat Mass, Distribution and Liver Determine Necessary Insulin Doses to Reach Target Ryysy et al, Diabetes, 2000, 49: Type 2 patients insulin treated for > 1 year, HbA1c: % Doses: IU/d (Bedtime NPH + metformin), Weight: kg Correlations with insulin absorption Visceral fat (ml) -0,73 p<0,0004 SC fat (ml) -0,60 p<0,0072 BMI -0,59 p<0,006 Correlations with insulin dose to suppress endogenous glucose production Liver steatosis (%) 0,72 p<0,0013 SC fat (ml) 0,67 p<0,0065 Body fat mass (kg) 0,60 p<0,01 Insulin doses needed to reach glucose control depends on : 1) Liver steatosis (r=0,76; p<0,0004) 2) waist/hip ratio (r=0,69; p<0,0008) 3) BMI (r=0,68; p<0,0009)
7 % reduction of hypos Glargine vs Daily NPH in Type 2 Diabetes: Meta-Analysis Rosenstock et al, Diabetes Care, Glargine (n=1142) vs daily NPH (n=1162) HbA1c < 7% : 30,8 % vs. 32,1 % (NS) 0 Hypoglycemia Nocturnal Hypos Severe Hypos Noct. Severe Hypos P = P < P = P =
8 [Glulisine vs. Regular Insulin] + NPH Twice Daily in Type 2 Diabetes Dailey et al, Diabetes Care, patients, 26 weeks follow-up HbA1c decrease from baseline (%) Post-breakfast blood glucose (mg/dl) Post-dinner blood glucose (mg/dl) Regular + NPH x 2/day 0.3 % Glulisine + NPH x 2/day 0.46 % (p=0.0029) 156 (p<0.05) 154 (p<0.05) Hypoglycemia and weight = no difference
9 [NPH vs. DETEMIR] + ASPART in Type 2 Diabetes Haak et al, Diabetes Obes Metab,, patients, 26 weeks follow-up HbA1c decrease from baseline (%) Between-day intra-subject blood glucose variability Weight gain (kg) NPH + ASPART 0.4 % (p=0.0001) Higher DETEMIR + ASPART 0.2% (p=0.004) Lower (p=0.021) (p=0.017)
10 [NPH+Regular]] vs. [Detemir+Aspart[ Detemir+Aspart] ] in Type 2 Diabetes Mellitus Raslova et al, Diabetes Res Clin Pract,, patients, 22 weeks follow-up HbA1c decrease from baseline (%) NPH + (Regular x 3/day) 0.58 Detemir + (Aspart x 3/day) 0.65 Between-day intra- suject blood glucose variability (mmol/l) Weight gain (kg) (p<0.001) 0.51 (p = 0.038) No significant difference on hypos
11 Effectiveness of Inhaled Insulin Exubera TM in Type 2 Diabetes Hollander et al., Diabetes Care 2004;27: Mean A1c (%) Screening Baseline Duration of treatment (weeks) Inhaled insulin (n=149) SC insulin (n=149)
12 Exubera TM in Type 2 Diabetes: Change in Body Weight (6 Months) Hollander et al., Diabetes Care 2004;27: Mean weight change (kg) Inhaled SC
13 Current Experience of Glucose Control with Insulin Injections in Type 2 Diabetes Evolution of insulin therapy toward basal-bolus bolus is needed to reach target. High insulin doses are commonly requested, according to fat distribution and liver steatosis. Insulin analogues decrease occurrence of hypos, improve glucose stability, may reduce weight gain but often fail in further lowering of HbA1c. Expected benefit of inhaled insulin looks minor, except for the acceptance of insulin and perhaps for weight control.
14 What Can We Expect from Insulin Pumps in Type 2 Diabetes?
15 IV Insulin Infusion Followed by One-year CSII in 8 Severely Resistant Type 2 Patients Pouwels et al, Diabetic Medicine, Baseline 6 months 9 months 12 months Follow-up of HbA1c using CSII for 1 year With Weight stability p < vs. Baseline p < vs. Baseline Effects of 4 weeks with IV insulin infusion
16 Forty-week Experience with CSII in 10 Severely Obese Type 2 Patients Wainstein et al, Diabetes Care, 2001 Daily Insulin Dose (IU/kg) Weight (kg) HbA1c (%) Baseline / / / After 40 weeks / / /- 0.76
17 Does it mean that insulin pump is only good for me? No Sir, we shall perform randomized studies now!
18 CSII [Aspart[ Aspart] ] vs. Multiple Daily Insulin Injections [Aspart + NPH] in Type 2 Diabetes: a Randomized, Parallel-Group Group,, 24-week Study Raskin P et al, Diabetes Care 2003, 26: ,2 8 HbA1c (%) 7,8 7,6 7,4 CSII MDI 7,2 7 Baseline 24 weeks P<0.05 vs. baseline
19 Baseline and End-of of-study Eight Point Blood Glucose Profiles (ITT) * p = 0.02
20 Change-from from-baseline Improvements in Patient Satisfaction Subscores at the End of Study * p<0.025 ** p<0.01 *** p<0.001
21 For sure, they will never try to randomize me Don t be so negative, it may happen! and for now, don t move!!
22 Insulin [lispro[ lispro] ] Pump Therapy vs. Multiple Daily Injections [Regular + NPH] in Obese Type 2 Diabetic Patients J Wainstein et al, Diabetic Medicine, Type 2 insulin-treated patients (BMI:( ; ; HbA1c > 8.5%; insulin doses > 1 iu/kg/d; metformin), 2 x 18-week randomized cross-over over study, 12-week wash-out b/w periods, 29 completers Direct treatment effect by group, ITT analysis
23 The Results of this Study Favour Pump Therapy for hard-to to-control Type 2 Obese Patients Take your hands away of my pump!!! Gee! That s fun. Can I be randomized, too?
24 CSII [lispro[ lispro] ] vs. Multiple Daily Injections [lispro[ + glargine] ] in Adults older than 60 years Herman WH et al, Diabetes Care, Type 2 insulin-treated patients (Age( > 60; BMI: 32; HbA1c: 8.2%), 12-month randomized parallel study, 98 completers HbA1c (%) CSII o MDI Study month No difference in weight gain, incidence of hypos, daily insulin doses, QoL indices
25 OK for oldies, but what about us, playing rugby? Don t look for my pump, it s internal!
26 ) ) ) ) ) What is an Internal Insulin Pump? Sideport Titanium case (81 x 20 mm, 146 g) Catheter ter Subcutaneous Part Anchoring Flange Intraperitoneal Part MODEL SN ) ) ) ) ) Telemetry Programmer Central Port Anchoring hoops Medtronic-MiniMed MiniMed Implantable Pump, model 2007
27 HbA1c (%) Randomized, Controlled,, Prospective Study: : Implantable Pump vs. MDI in 122 Type 2 Patients ,85 7,54 8,77 7,34 Saudek et al,, JAMA 1996 SD BG (mg/dl) ,5 Weight (kg) ,8 initial 12 months 101, MDI IMP PUMP 20 MDI IMP PUMP 90 MDI IMP PUMP p < 0,001 vs initial p < 0,01 vs MDI p < 0,001 vs MDI
28 What Can We Expect from Insulin Pumps in Type 2 Diabetes? Insulin pumps are usable at any age with at least similar effectiveness, no further weight gain, no more acute events when compared with MDI using analogues or not. They may provide better satisfaction because of increased flexibility of use and avoidance of injections, as they do in type 1 diabetic patients. They may help in more efficient glucose control in severely resistant, obese patients. Further studies are needed to assess cost- effectiveness and benefit.
29 Insulin Pump Therapy in Type 2 Diabetes Yes, when glucose control with MDI looks as an impossible mission. No, there is no reason for any diktat against pump in these patients. We will probably have to think more of using pumps in the future: younger patients, QoL issues, glucose sensors
30 Be Welcome in Montpellier to Know More about The Future of Diabetes Therapy! 1st European Diabetes Technology and Transplantation Meeting
The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationInsulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net
Insulin: Breaking Barriers Enhancing Therapies Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Questions To Address Who are candidates for insulin? When do we start insulin? How do the different types of
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationPresent and Future of Insulin Therapy: Research Rationale for New Insulins
Present and Future of Insulin Therapy: Research Rationale for New Insulins Current insulin analogues represent an important advance over human insulins, but clinically important limitations of these agents
More informationInsulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults
Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults Stock # 45-11647 Revised 10/28/10 Glycemic Goals 1,2 Individualize goal based on patient risk factors A1c 6%
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationIntensifying Insulin In Type 2 Diabetes
Intensifying Insulin In Type 2 Diabetes Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine University of North Dakota School of Medicine and Health Sciences Assistant
More informationScottish Medicines Consortium
Scottish Medicines Consortium insulin glulisine for subcutaneous injection 100 units/ml (Apidra ) No. (298/06) Sanofi Aventis 4 August 2006 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationTherapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2
Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick
More informationInsulin therapy in various type 1 diabetes patients workshop
Insulin therapy in various type 1 diabetes patients workshop Bruce H.R. Wolffenbuttel, MD PhD Dept of Endocrinology, UMC Groningen website: www.umcg.net & www.gmed.nl Twitter: @bhrw Case no. 1 Male of
More informationINSULIN ALGORITHM FOR TYPE 2 DIABETES MELLITUS IN CHILDREN 1 AND ADULTS
Publication # 45-11647 Targets*
More informationADJUSTING INSULIN DOSES CONFLICTS OF INTEREST
ADJUSTING INSULIN DOSES CONFLICTS OF INTEREST Vahid Mahabadi, MD Research grants from Sanofi and Amylin Pharmaceutical Companies Mayer B. Davidson, MD Advisory Board Sanofi Pharmaceutical Company Chief
More informationCLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies
Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin
More informationInsulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types
Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by
More informationtips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden:
tips Top International Publications Selection Insulin Pump Users Early detection of insulin deprivation in continuous subcutaneous insulin infusion-treated Patients with TD Population Study of Pediatric
More informationInsulin Initiation and Intensification
Insulin Initiation and Intensification ANDREW S. RHINEHART, MD, FACP, CDE MEDICAL DIRECTOR AND DIABETOLOGIST JOHNSTON MEMORIAL DIABETES CARE CENTER Objectives Understand the pharmacodynamics and pharmacokinetics
More informationIMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL
464 IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL PRACTICE STEPHAN A SCHREIBER AND ANIKA RUßMAN ABSTRACT
More informationPractical Applications of Insulin Pump Therapy in Type 2 Diabetes
Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Wendy Lane, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title. Summary
More informationDiabetes Management Tube Feeding/Parenteral Nutrition Order Set (Adult)
Review Due Date: 2016 May PATIENT CARE ORDERS Weight (kg) Known Adverse Reactions or Intolerances DRUG No Yes (list) FOOD No Yes (list) LATEX No Yes ***See Suggestions for Management (on reverse)*** ***If
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationDiabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
More informationDIABETES MEDICATION INSULIN
Section Three DIABETES MEDICATION INSULIN This section will tell you: About insulin. How to care and store your insulin. When to take your insulin. Different ways of taking insulin. WHAT IS INSULIN? Insulin
More informationInsulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus
Insulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus Louis Haenel, IV, DO, FACOI, FACE Endocrinology Roper Hospital Charleston, SC Dr. Louis Haenel IV has disclosed
More informationA new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration
of nurse A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration 1. Check times for point of care meter blood glucose testing. Pre-Breakfast
More informationShort-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis
ORIGINAL ARTICLE doi: 10.1111/j.1463-1326.2008.00934.x Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis E. Mannucci, M. Monami and N. Marchionni Department of
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationType 2 Diabetes Adult Outpatient Insulin Guidelines Sutter Medical Foundation. February 2011.
Type 2 Diabetes Adult Outpatient Insulin Guidelines. GENERAL RECOMMENDATIONS Start insulin if A1C and glucose levels are above goal despite optimal use of other diabetes medications. (Consider insulin
More informationInsulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB
Insulin switch & Algorithms Rotorua GP CME June 2011 Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Goal of workshop Insulin switching make the necessary move Ensure participants are confident with Recognising
More informationEASD/ADA 2015 Highlights- insulin. Dr Jarl Hellman
EASD/ADA 2015 Highlights- insulin Dr Jarl Hellman Innehåll NPH Epidemiologi Nya insuliner Basinsulinets bäste vän exklusive hund och UKPDS? G.B Bolli Hypoglykemi - NPH Exogenous insulin and risk of all-cause
More informationHealth Technology Appraisal- Continuous subcutaneous insulin infusion for the treatment of diabetes (review)
Health Technology Appraisal- Continuous subcutaneous insulin infusion for the treatment of diabetes (review) Submission on behalf of British Dietetic Association (BDA) Following consultation with the BDA
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
PL Detail-Document #300128 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Initiation and Adjustment of Insulin Regimens for Type
More informationInsulin Administration: What You Don t Know May Hurt Your Patient
Insulin Administration: What You Don t Know May Hurt Your Patient Jaime A. Davidson, MD, FACP, MACE Clinical Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Jaime A. Davidson,
More informationDistinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationGlucose Tolerance Categories. Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationA Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Basal Dosing
Journal of Diabetes Science and Technology Volume 1, Issue 1, January 2007 Diabetes Technology Society ORIGINAL ARTICLES A Prospective Evaluation of Insulin Dosing Recommendations in Patients Allen B.,
More informationInsulin therapy in type 2 diabetes When and how? Disclosures. Learning Objectives. None relevant to today s talk
Insulin therapy in type 2 diabetes When and how? Cecilia C Low Wang, MD Univ Colorado AMC SOM Department of Medicine Division of Endocrinology, Metabolism, and Diabetes Disclosures None relevant to today
More informationAbdulaziz Al-Subaie. Anfal Al-Shalwi
Abdulaziz Al-Subaie Anfal Al-Shalwi Introduction what is diabetes mellitus? A chronic metabolic disorder characterized by high blood glucose level caused by insulin deficiency and sometimes accompanied
More informationDonovan Victorine Pharm.D. BCACP Clinical Pharmacy Specialist Boise VA Medical Center. U-500 Insulin
Donovan Victorine Pharm.D. BCACP Clinical Pharmacy Specialist Boise VA Medical Center U-500 Insulin Understand differences between U-500 concentrated insulin and standard insulin formulations Recognize
More informationResident s Guide to Inpatient Diabetes
Resident s Guide to Inpatient Diabetes 1. All patients with diabetes of ANY TYPE, regardless of reason for admission, must have a Hemoglobin A1C documented in the medical record within 24 hours of admission
More informationFunc%onal insulin therapy: rela%onship to carbohydrate intake
Func%onal insulin therapy: rela%onship to carbohydrate intake Prof. Andrej Janež MD, PhD University Medical Centre Ljubljana, Slovenia Conflict of interests Merck Sharp&Dohme, Novo Nordisk, NovarEs, Boehringer
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationSponsor / Company: Sanofi Drug substance(s): HOE901 (insulin glargine)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationInsulin Therapy. Endocrinologist. H. Delshad M.D. Research Institute For Endocrine Sciences
Insulin Therapy H. Delshad M.D Endocrinologist Research Institute For Endocrine Sciences Primary Objectives of Effective Management A1C % 9 8 Diagnosis SBP mm Hg LDL mg/dl 7 145 130 140 100 Reduction of
More informationThe U.K. Prospective Diabetes Study
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Comparison of two treatment algorithms using insulin glargine
More informationInsulin Pumps in Diabetes Management By Rita Carey Rubin, MS, RD, CDE. Suggested CDR Learning Codes: 5190, 5400, 5410, 5420; Level 2
Insulin Pumps in Diabetes Management By Rita Carey Rubin, MS, RD, CDE Suggested CDR Learning Codes: 5190, 5400, 5410, 5420; Level 2 Controlling diabetes is one of the most important challenges facing patients
More informationPresented By: Dr. Nadira Husein
Presented By: Dr. Nadira Husein I have no conflict of interest Disclosures I have received honoraria/educational grants from the following: Novo Nordisk, Eli Lilly, sanofi-aventis, Novartis, Astra Zeneca,
More informationLong-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis
ORIGINAL ARTICLE doi: 10.1111/j.1463-1326.2008.00976.x Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis M. Monami, N. Marchionni and E. Mannucci Unit of Geriatrics,
More informationInsulin Pens & Improving Patient Adherence
Insulin Pens & Improving Patient Adherence Bonnie Pepon, RN, BSN, CDE Certified Diabetes Educator Conemaugh Diabetes Institute Kip Benko, MD FACEP Asst Clinical Professor University of Pittsburgh School
More informationWorkshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
More informationAims To compare the effects on glycaemic control after using continuous subcutaneous insulin infusion (CSII) or insulin glargine.
DOI: 10.1111/j.1464-5491.2004.01444.x Optimization of basal insulin delivery in Type 1 diabetes: Oxford, DME Diabetic 0742-3071 Blackwell 21 Original UK Article article Medicine Publishing, of basal insulin
More informationContinuous Subcutaneous Insulin Infusion (CSII)
IMPORTANCE OF FOCUS CSII (Insulin pumps) have been used for more than 35 years. In the U.S. in 2005, the level of insulin pump penetration was estimated at 20 to 30% in patients with type 1 diabetes mellitus
More informationDesigner Insulins. History case 1. Follow up - case 1. Follow up - case 1. History - case 2. 24 hr glucose profile - case 1
History case 1 33 yr old male bank manager Designer Insulins Dr A Qureshi MB ChB (Edin), MD (Lon), CCT (Lon), FRCP (Lon) Consultant in Endocrinology, Diabetes and General Internal Medicine w w w. e n d
More informationMost patients with T2DM will eventually require insulin therapy. ADA Glycemic Control Targets. What are some of the obstacles?
ADA Glycemic Control Targets A1C < 7% Preprandial plasma glucose 70-130 mg/dl Postprandial plasma glucose (PPG)
More informationA Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Bolus Dosing
Journal of Diabetes Science and Technology Volume 1, Issue 1, January 2007 Diabetes Technology Society ORIGINAL ARTICLES A Prospective Evaluation of Insulin Dosing Recommendations in Patients Allen B.,
More informationINSULIN THERAPY FOR CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES
INSULIN THERAPY FOR CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES Young Jun Rhie, M.D. Department of Pediatrics Korea University Ansan Hospital Introduction 1 Children and adolescents with type 1 diabetes
More informationInsulin glulisine (GLU) is a rapid-acting insulin analog. Original Article
DIABETES TECHNOLOGY & THERAPEUTICS Volume 13, Number 6, 2011 ª Mary Ann Liebert, Inc. DOI: 10.1089/dia.2010.0224 Original Article Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered
More informationSolomon S. Steiner, Lutz Heinemann, Roderike Pohl, Frank Flacke, Andreas Pfützner, Patrick V. Simms, Marcus Hompesch. EASD September 18, 2007
Pharmacokinetics and Pharmacodynamics of Insulin VIAject TM, Insulin Lispro and Regular Human Insulin When Injected Subcutaneously Immediately Before a Meal in Patients with Type 1 Diabetes. Solomon S.
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More information10 to 30 minutes ½ to 3 hours 3 to 5 hours. 30 60 minutes 1 to 5 hours 8 hours. 1 to 4 hours
Insulin Action There are several types of insulin. They are classified by how long they act: very fast, fast, slow and very slow acting. Each type of insulin has a certain time period in which it works.
More informationPeople with type 2 diabetes mellitus (T2DM) often require
DIABETES TECHNOLOGY & THERAPEUTICS Volume 12, Supplement 1, 2010 ª Mary Ann Liebert, Inc. DOI: 10.1089=dia.2009.0192 Insulin Pump Use in Type 2 Diabetes Bruce W. Bode, M.D., F.A.C.E. Abstract Continuous
More informationTen Ways to Prevent Insulin-Use Errors in Your Hospital. ASHP Research and Education Foundation May 14, 2014
Ten Ways to Prevent Insulin-Use Errors in Your Hospital ASHP Research and Education Foundation May 14, 2014 To Ask Questions and Adjust the Control Panel Expand or Collapse Type your question here Faculty
More informationCochrane Quality and Productivity topics
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus NICE has developed the Cochrane Quality and Productivity (QP) topics to help the NHS identify practices
More informationManagement of Hospital Hyperglycemia
Management of Hospital Hyperglycemia Asad Saeed, M.D. Director, Inpatient Diabetes Assistant Professor of Medicine Division of Endocrinology Department of Medicine University i of Minnesota Outline Clinical
More informationInsulin onset, peak and duration of action
Insulin onset, peak and duration of action Insulin was first discovered in the early 190 s. Before then, diabetes could not be treated. Insulin was then taken from cow and pig pancreases, but nearly all
More informationStarting Insulin. Disclosures. Starting Insulin. Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres
Starting Insulin Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres Disclosures Scientific Consultant Abbott, AstraZeneca, GSK, Merck, Sanofi-Aventis, Janssen- Ortho, Servier
More informationType 2 diabetes mellitus
Type 2 diabetes mellitus CLINICAL PRACTICE Management Guidelines for initiating insulin therapy BACKGROUND Insulin is often indicated for patients with suboptimally controlled type 2 diabetes mellitus,
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationThe Quantified Self on Steroids: Innovation in Devices, Pumps and Monitors
The Quantified Self on Steroids: Innovation in Devices, Pumps and Monitors Howard A. Wolpert, MD 1 Diabetes is different to many other conditions Patient/Self Managed 2 To achieve the therapeutic goals
More informationLipodystrophy: Metabolic and Clinical Aspects. Resource Room Slide Series
Lipodystrophy: Metabolic and Clinical Aspects Resource Room Slide Series Current Thinking About the Diagnosis and Treatment of the Insulin-Resistant State: How to Use Insulin Therapy Irl B. Hirsch, MD
More informationInsulin pen start checklist
Insulin pen start checklist Topic Instruction Date & Initials 1. Cognitive Assessment 2. Insulin Delivery loading appropriate mixing priming shot dialing up dose delivery of insulin 3. Insulin type/action
More informationStarting patients on the V-Go Disposable Insulin Delivery Device
Starting patients on the V-Go Disposable Insulin Delivery Device A simple guide for your practice For adult patients with Type 2 diabetes on basal insulin who need to take the next step Identify appropriate
More information(30251) Insulin SQ Prandial Carbohydrate
Diagnosis Patient MUST BE educated using carbohydrate counting for prial insulin coverage before hospitalization to be eligible for this order set Nursing Metered Glucose (Single Select Section) Metered
More informationGlucose Management University of Colorado Hospital
Glucose Management University of Colorado Hospital Bridget Everhart, MSN, NP, CDE Inpatient Diabetes Educator Bridget.Everhart@uch.edu M F Pager 303 266-7898 UCH Diabetes Program Michael McDermott MD Diabetes
More informationInsulin Pump Therapy
CHILDREN S SERVICES Insulin Pump Therapy These guidelines are not intended for starting a patient on an insulin pump. They are intended to give staff not part of the diabetic team information regarding
More informationGlycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol
Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding
More informationLong term Weight Management in Obese Diabetic Patients Osama Hamdy, MD, PhD, FACE
Long term Weight Management in Obese Diabetic Patients Osama Hamdy, MD, PhD, FACE Medical Director, Obesity Clinical Program, Director of Inpatient Diabetes Management, Joslin Diabetes Center Assistant
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationBIAsp30 A 1 chieve Tehran 31 July 2015
BIAsp30 A 1 chieve Tehran 31 July 2015 Beginning insulin with biphasic insulin aspart 30: experience from the A 1 chieve study Professor Philip Home Newcastle University Presenter and sponsor duality of
More informationGlycaemic Control in Adults with Type 1 Diabetes
Glycaemic Control in Adults with Type 1 Diabetes Aim(s) and objective(s) This document aims to provide guidance on good clinical practice in managing glycaemic control in adult patients with Type 1 Diabetes
More informationINTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL
INTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL Presented by: Leyda Callejas PGY5 Endocrinology, Diabetes and Metabolism Acknowledgements: Dr. P Orlander Dr. V Lavis Dr. N Shah
More informationTypes of insulin and How to Use Them
Diabetes and Insulin Pumps Amy S. Pullen Pharm.D ISHP Spring Meeting April 2012 Objectives Describe the different types of insulin used in diabetes Identify the types of insulin that are compatible with
More informationCalculating Insulin Dose
Calculating Insulin Dose First, some basic things to know about insulin: Approximately 40-50% of the total daily insulin dose is to replace insulin overnight, when you are fasting and between meals. This
More informationType 2 Diabetes - Pros and Cons of Insulin Administration
Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes? Cons: Suad Efendic Karolinska Institutet, Sweden The Diabetes Management Situation Today Diabetes is a growing
More informationEpidemiology of Diabetes (US data released 1/26/2011)
Therapy in Diabetes Mellitus Part 1 Lekshmi T. Nair, MD, MHS Assistant Professor Department of Internal Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio State University Wexner Medical
More informationUW MEDICINE PATIENT EDUCATION. Using Insulin. Basic facts about insulin and self-injection. What is insulin? How does diabetes affect the body?
UW MEDICINE PATIENT EDUCATION Using Insulin Basic facts about insulin and self-injection This handout explains what insulin is, the different types of insulin, how to store it, how to give an injection
More informationPremixed Insulin for Type 2 Diabetes. a gu i d e f o r a d u lt s
Premixed Insulin for Type 2 Diabetes a gu i d e f o r a d u lt s March 2009 What This Guide Covers / 2 Type 2 Diabetes / 3 Learning About Blood Sugar / 4 Learning About Insulin / 5 Comparing Medicines
More informationMANAGEMENT OF TYPE - 1 DIABETES MELLITUS
MANAGEMENT OF TYPE - 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationA Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or
A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl
More informationBASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS
BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS C O N T A C T D I A B E T E S S E R V I C E S F O R M O R E I N F O R M A T I O N 8 4 7-9 1 7-6 9 0 7 THIS SLIDE PRESENTATION WAS PREPARED BY SUE DROGOS,
More informationDavid O'Neal MD, FRACP, Alicia Jenkins MD, FRACP University of Melbourne, Department of Medicine, St. Vincent's Hospital, Melbourne, Australia
Page 20 Vol.1 No.3 2006 Insulin Pump Therapy in Type I Diabetes: A Brief Review of the Evidence David O'Neal MD, FRACP, Alicia Jenkins MD, FRACP University of Melbourne, Department of Medicine, St. Vincent's
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationSafety and Effectiveness of Modern Insulin Therapy: The Value of Insulin Analogs
STEPHEN BRUNTON, MD Cabarrus Family Medicine Residency Program, Charlotte, NC Safety and Effectiveness of Modern Insulin Therapy: Dr Brunton is director of faculty development at the Cabarrus Family Medicine
More informationEveryday Practice: Diabetes Mellitus
THE NATIONAL MEDICAL JOURNAL OF INDIA VOL. 20, NO. 5, 2007 245 Everyday Practice: Diabetes Mellitus Insulin therapy for patients with type 2 diabetes mellitus NISHA R. S., E. BHATIA INTRODUCTION India
More informationGlobal Guideline for Type 2 Diabetes
INTERNATIONAL DIABETES FEDERATION, 2005 Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes Chapter 10: Glucose control: insulin therapy Copyright All rights reserved. No part of this publication
More informationRight Insulin Regimen
Focus on CME at l Université McGill University de Montréal What is the Right Insulin Regimen for my Patient? Jean-Pierre Hallé, MD, FRCPC, and Donald Breton, MD, FRCPC What can I do to improve my patient
More information